Douglas Adkins

1.3k total citations · 1 hit paper
19 papers, 659 citations indexed

About

Douglas Adkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Douglas Adkins has authored 19 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Douglas Adkins's work include Cancer Immunotherapy and Biomarkers (5 papers), Head and Neck Cancer Studies (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Douglas Adkins is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Head and Neck Cancer Studies (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Douglas Adkins collaborates with scholars based in United States, Spain and France. Douglas Adkins's co-authors include Gary K. Schwartz, Mark Agulnik, Ilaria Conti, Gregory Pennock, Gaurav Shah, Robin L. Jones, William D. Tap, Damien M. Cronier, Robert Ilaria and Jan Cosaert and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Douglas Adkins

16 papers receiving 647 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

2016 436 citations William D. Tap, Robin L. Jones et al. The Lancet profile →

Peers

Countries citing papers authored by Douglas Adkins

Since Specialization

Citations

This map shows the geographic impact of Douglas Adkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Adkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Adkins more than expected).

Fields of papers citing papers by Douglas Adkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Adkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Adkins. The network helps show where Douglas Adkins may publish in the future.

Co-authorship network of co-authors of Douglas Adkins

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Adkins. A scholar is included among the top collaborators of Douglas Adkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Adkins. Douglas Adkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation 2025 ·Oral Oncology ·Thomas F. Barrett, Anthony J. Apicelli, (unknown), Patrik Pipkorn, Paul Zolkind, Jason T. Rich, R. Alex Harbison, (unknown), Hiram A. Gay, Nikhil Ram-Mohan, Michael J. Moravan, Jennifer De Los Santos, Peter Oppelt, Douglas Adkins, Ryan S. Jackson, Sidharth V. Puram	0
2	Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). 2025 ·Journal of Clinical Oncology ·Jérôme Fayette, Aron Popovtzer, Martin Förster, Douglas Adkins, (unknown), G. Lefebvre, Jacob Thomas, Fiona Collinson, Ludovic Doucet, Nathaniel Bouganim, Lei Liu, (unknown), Richard C. Gregory, (unknown), Radha Ramesh, Bingyan Wu, Jeffrey J. Raizer, (unknown), Ammar Sukari	0
3	Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. 2025 ·Journal of Clinical Oncology ·Douglas Adkins, Robert I. Haddad, Yungan Tao, Christophe Le Tourneau, Nancy Y. Lee, Kunal K. Sindhu, Rebecca D. Chernock, Makoto Tahara, Kevin J. Harrington, A L Klochikhin, Irene Braña, Gustavo Vasconcelos Alves, Brett Hughes, Marc Oliva, Iane Pinto Figueiredo Lima, Tsutomu Ueda, (unknown), (unknown), Behzad Bidadi, Ravindra Uppaluri	2
4	Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial 2024 ·The Lancet Oncology ·Douglas Adkins, Jessica Ley, Jingxia Liu, Peter Oppelt	5
5	KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC) 2023 ·European Journal of Surgical Oncology ·A L Klochikhin, Robert I. Haddad, Amichay Meirovitz, Sufia Safina, Irene Braña, Christophe Le Tourneau, Ravindra Uppaluri, Nancy Y. Lee, Ezra E.W. Cohen, Rebecca D. Chernock, William H. Westra, Hong Liu, Burak Gümüşçü, (unknown), Douglas Adkins	3
6	Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A0201 positive patients with HPV16+ OPSCC. 2023 ·Journal of Clinical Oncology* ·Jesse M. Zaretsky, Jessica Ley, Peter Oppelt, (unknown), Thomas F. Barrett, Ryan S. Jackson, Patrik Pipkorn, Randal C. Paniello, Jason T. Rich, Jingxia Liu, (unknown), (unknown), Wade L. Thorstad, Steven N. Quayle, Raymond J. Moniz, Apollina Goel, Matteo Levisetti, Anish Suri, Sidharth V. Puram, Douglas Adkins	1
7	Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers. 2022 ·Journal of Clinical Oncology ·Siqing Fu, Lisle M. Nabell, Alexander T. Pearson, Rom S. Leidner, Douglas Adkins, Marshall R. Posner, Jorge J. Nieva, Debra L. Richardson, (unknown), Sanjay Goel, Stuart J. Wong, Alan L. Ho, Ari Rosenberg, Matthew H. Taylor, (unknown), (unknown), Xiaoping Qing, (unknown), Katia Schlienger, David G. Pfister	3
8	A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma. 2022 ·Journal of Clinical Oncology ·Glenn J. Hanna, Cesar A. Perez, Alan L. Ho, Maura L. Gillison, Douglas Adkins, (unknown), (unknown), Mollie Leoni, (unknown), (unknown), Alex Dmitrienko	2
9	First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors 2022 ·Investigational New Drugs ·Todd M. Bauer, Byoung Chul Cho, Rebecca S. Heist, Lyudmila Bazhenova, Theresa L. Werner, Sanjay Goel, Dong‐Wan Kim, Douglas Adkins, Richard D. Carvajal, Ajjai Alva, Keith D. Eaton, Judy Wang, Yong Liu, Xiaohong Yan, (unknown), Saskia Neuteboom, Richard C. Chao, Shubham Pant	28
10	Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial. 2022 ·Journal of Clinical Oncology ·Aaron S. Mansfield, Vivek Subbiah, Martin Schüler, Viola W. Zhu, Julien Hadoux, Marcia S. Brose, Giuseppe Curigliano, Lori J. Wirth, Elena Garralda, Douglas Adkins, Yann Godbert, Myung‐Ju Ahn, Philippe A. Cassier, Byoung Chul Cho, Chia‐Chi Lin, Hui Zhang, Alena Zalutskaya, Teresa Barata, Astrid Scalori, Matthew H. Taylor	8
11	TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. 2022 ·Journal of Clinical Oncology ·Douglas Adkins, (unknown), Julio A. Peguero, John Park, Antonio López–Pousa, Willem Lybaert, Irene Braña, Bernard Doger, Frédéric Triebel	4
12	Outcomes of Patients With Single-Node Metastasis of Human Papillomavirus–Related Oropharyngeal Cancer Treated With Transoral Surgery 2020 ·JAMA Otolaryngology–Head & Neck Surgery ·Stephanie Chen, Parul Sinha, (unknown), (unknown), Dorina Kallogjeri, Patrik Pipkorn, Jason T. Rich, José P. Zevallos, Randal C. Paniello, Sidharth V. Puram, (unknown), Eric J. Moore, Peter Oppelt, (unknown), Douglas Adkins, Mackenzie Daly, Hiram A. Gay, Wade L. Thorstad, Ryan S. Jackson	5
13	An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis. 2019 ·Journal of Clinical Oncology ·Assuntina G. Sacco, Ruifeng Chen, (unknown), Deborah Jean Lee Wong, Francis P. Worden, Douglas Adkins, Emily Pittman, Karen Messer, Kathryn A. Gold, Gregory A. Daniels, Paul Swiecicki, Brian C. Sutton, (unknown), Ezra E.W. Cohen	14
14	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial breakdown → 2016 ·The Lancet ·William D. Tap, Robin L. Jones, Brian A. Van Tine, Bartosz Chmielowski, Anthony Elias, Douglas Adkins, Mark Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory Pennock, Meera Hameed, Gaurav Shah, Amy Qin, Ashwin Shahir, Damien M. Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K. Schwartz	436
15	A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors. 2016 ·Journal of Clinical Oncology ·Todd M. Bauer, Douglas Adkins, Gary K. Schwartz, Theresa L. Werner, Ajjai Alva, David S. Hong, Richard D. Carvajal, Mansoor N. Saleh, Lyudmila Bazhenova, Sanjay Goel, Keith D. Eaton, Robert D. Siegel, (unknown), Richard C. Lauer, Saskia Neuteboom, (unknown), Isan Chen, James G. Christensen, Richard C. Chao, Rebecca S. Heist	9
16	A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors. 2015 ·Journal of Clinical Oncology ·Gary K. Schwartz, Douglas Adkins, Rebecca S. Heist, Maura Abbott, (unknown), Richard C. Chao, Saskia Neuteboom, Isan Chen, James G. Christensen, Todd M. Bauer	3
17	Antiangiogenic Agents for Nonmalignant Brain Tumors 2013 ·Journal of Neurological Surgery Part B Skull Base ·Joshua B. Rubin, David Tran, Douglas Adkins, Shahid Waheed, Timothy E. Hullar, David H. Gutmann, John A. Evans, Jeffrey R. Leonard, Gregory J. Zipfel, Michael R. Chicoine, Ammar H. Hawasli	27
18	A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma 2011 ·Oncology ·Kristen N. Ganjoo, Lee D. Cranmer, James E. Butrynski, Daniel A. Rushing, Douglas Adkins, Scott H. Okuno, Gustavo Lorente, Stew Kroll, Virginia K. Langmuir, Sant P. Chawla	65
19	Donor-Derived Acute Promyelocytic Leukemia in a Liver-Transplant Recipient 1999 ·New England Journal of Medicine ·Imre Bodó, Marion G. Peters, Jerald P. Radich, Jay L. Hess, Morey A. Blinder, Michael S. Watson, Richard Van Rheeden, (unknown), Jeffrey A. Lowell, Randy A. Brown, John F. DiPersio, Douglas Adkins	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact